17:55:57 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-19 Bokslutskommuniké 2024
2024-11-13 Kvartalsrapport 2024-Q3
2024-08-20 Kvartalsrapport 2024-Q2
2024-05-21 Ordinarie utdelning BICO 0.00 SEK
2024-05-20 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-20 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-22 Kvartalsrapport 2023-Q2
2023-05-10 Ordinarie utdelning BICO 0.00 SEK
2023-05-09 Årsstämma 2023
2023-05-04 Kvartalsrapport 2023-Q1
2023-02-22 Bokslutskommuniké 2022
2022-12-14 Extra Bolagsstämma 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-18 Kvartalsrapport 2022-Q1
2022-04-27 Ordinarie utdelning BICO 0.00 SEK
2022-04-26 Årsstämma 2022
2022-02-23 Bokslutskommuniké 2021
2021-11-17 Extra Bolagsstämma 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-04-27 Ordinarie utdelning BICO 0.00 SEK
2021-04-26 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-12-18 Ordinarie utdelning BICO 0.00 SEK
2020-12-17 Extra Bolagsstämma 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-04-09 Kvartalsrapport 2020-Q2
2020-01-20 Kvartalsrapport 2020-Q1
2020-01-10 Split BICO 1:4
2019-12-19 Ordinarie utdelning BICO 0.00 SEK
2019-12-18 Årsstämma 2020
2019-10-24 Bokslutskommuniké 2019
2019-08-26 Extra Bolagsstämma 2019
2019-07-11 Kvartalsrapport 2019-Q3
2019-04-10 Kvartalsrapport 2019-Q2
2018-12-14 Ordinarie utdelning BICO 0.00 SEK
2018-12-13 Årsstämma 2019
2018-10-24 Bokslutskommuniké 2018
2018-07-11 Kvartalsrapport 2018-Q3
2018-04-11 Kvartalsrapport 2018-Q2
2018-01-17 Kvartalsrapport 2018-Q1
2017-12-15 Ordinarie utdelning BICO 0.00 SEK

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
BICO Group är verksamma inom medicinteknik. Bolaget är specialiserade inom biokonvergens och tillhandahåller teknik, produkter och tjänster för biologi. Med fokus på applikationsområdena bioprintning, multiomics, cellinjeutveckling och diagnostik utvecklar och marknadsför bolaget teknik som gör det möjligt för forskare att odla celler i 3D-miljöer, genomföra läkemedelsscreening och skriva ut mänskliga vävnader och organ för medicinsk, läkemedels- och kosmetisk industri.
2023-07-27 19:00:00

BICO is initiating the next phase in their integration process, during July 2023, with the focus on executing on a further integrated and customer-centric operating model to capitalize on cross-selling, marketing, and commercial synergies. This work will be carried out during the coming quarters and will be further explained in the Q2 2023 report.

Rationale and scope
The last few years for BICO have been characterized by a growth by acquisition phase, spurred on by the strategic acquisition of companies to gain valuable market share in critical customer areas and technologies. Following this growth by acquisition phase, since mid-2022 and as part of the first phase of integration, BICO has been focused on financial integration; implementing internal control and harmonizing financial processes. Today, BICO has significant alignment across its financial reporting in the group companies and can shift its focus to the next phase of the M&A integration process.

The next stage in the integration processes focuses on realizing commercial synergies i.e., cross-selling, co-marketing, and providing increased value to each customer. This second stage builds on the M&A rationale and strengthens our market position, contributes to profitable growth, and solidifies the group’s competitive advantage within specific markets. In this stage, the Group will continue to build an efficient and customer-centric operating model to better realize its commercial potential. Delivering an end-to-end product portfolio while streamlining the organization and keeping CAPEX and OPEX at industry-standard levels. Execution will occur on a mid-term basis and occur at the Group level and within Group companies.

The timing is driven by BICO’s focus on execution and industrializing our operations following the more acquisition-oriented phase. This will set direction for the upcoming years to make sure that BICO can realize the value creation enabled by the acquisitions. The Board very much look forward to this vital transformation process.” says Rolf Classon, Chairman of the Board, BICO.

The team is dedicated to further capitalizing and realizing the full potential of the commercial portfolio and synergies while maintaining a profitable and streamlined organization. The commercial integration phase will help the organization stay focused on and deliver growth and profitability while building our customer-centric operating model to provide our customers across the globe with the best offering to accelerate their work.” says Erik Gatenholm, CEO and President, BICO.

Timeline for communication
BICO will give further details in the Q2 report which will be released on August 22, 2023. The full scope and the progress of the implementation will be presented during the Capital Markets Day, which will be held in conjunction with the release of BICO’s Q3 report on November 14, 2023.